State of the art of cervical cancer treatment in rare histologies.

Autor:	Arango-Bravo EA; Medical Oncology Department, National Institute of Cancerology (INCan), Mexico City, Mexico.; Clinical Investigation Department, National Institute of Cancerology (INCan), Mexico City, Mexico., Galicia-Carmona T; Medical Oncology Department, National Institute of Cancerology (INCan), Mexico City, Mexico.; Clinical Investigation Department, National Institute of Cancerology (INCan), Mexico City, Mexico., Cetina-Pérez L; Medical Oncology Department, National Institute of Cancerology (INCan), Mexico City, Mexico.; Clinical Investigation Department, National Institute of Cancerology (INCan), Mexico City, Mexico., Flores-de la Torre CB; Oncology Department, Campeche State Oncology Center, Campeche, Mexico., Enríquez-Aceves MI; Oncology Department, Regional Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Hospital León, León de los Aldama, Guanajuato, Mexico., García-Pacheco JA; Sistema Nacional de Investigadores (SNI), National Council of Science and Technology (CONACYT), Mexico City, Mexico., Gómez-García EM; Oncology Department, Metepec Cancer Treatment Center, Metepec, Estado de México, Mexico.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Jun 28; Vol. 14, pp. 1386294. Date of Electronic Publication: 2024 Jun 28 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1386294
Abstrakt:	The objective of this review is to summarize the current scientific evidence to formulate clinical recommendations regarding the classification, diagnostic approach, and treatment of rare histological subtypes of cervical cancer; neuroendocrine carcinoma, gastric-type mucinous adenocarcinoma, and glassy cell adenocarcinoma. These histological subtypes are generally characterized by their low frequency, aggressive biological behavior, certain chemoradioresistance, and consequently, high recurrence rates with a deleterious impact on survival. Molecular studies have identified several associated mutations in neuroendocrine carcinoma (PIK3CA, MYC, TP53, PTEN, ARID1A, KRAS, BRCA2) and gastric-type adenocarcinoma (KRAS, ARID1A, PTEN) that may serve as molecular targets. While adenocarcinomas are typically treated and classified based on squamous histology across early, locally advanced, and advanced stages, the treatment strategies for neuroendocrine carcinomas in early stages or locally advanced cases differ, particularly in the sequencing of administering chemotherapy, chemoradiotherapy, or surgery. The chemotherapy regimen is based on etoposide plus cisplatin (EP). Unlike squamous cell carcinomas, immune checkpoint inhibitors are yet to establish a standard role in the treatment of recurrent neuroendocrine carcinomas due to the absence of clinical trials. Regarding glassy cell adenocarcinomas and gastric-type adenocarcinoma, the potential use of immunotherapy in advanced stages/disease requires further evaluation through international collaborations, given the limited number of cases. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Arango-Bravo, Galicia-Carmona, Cetina-Pérez, Flores-de la Torre, Enríquez-Aceves, García-Pacheco and Gómez-García.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu